Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Nutt

Showing results (71-80 of 179) with videos related to

Pageof 18
Sort By:
Lancet (London, England)|March 16, 2016
Ketamine--the real perspectivePolly Taylor, David Nutt, Val Curran, et al.
Journal of Psychopharmacology (Oxford, England)|April 30, 2015
European rating of drug harmsJan van Amsterdam, David Nutt, Lawrence Phillips, et al.
Nature Reviews. Neuroscience|April 21, 2011
Neuroscience in recession?Susan G Amara, Sten Grillner, Tom Insel, et al.
Addiction Biology|July 10, 2003
A pilot study on the effects of treatment with acamprosate on craving for alcohol in alcohol-dependent patientsAviv Weinstein, Barbara Feldtkeller, Adrian Feeney, et al.
JAMA Network Open|July 15, 2024
Interrupting the Psychedelic Experience Through Contextual Manipulation to Study Experience EfficacyLeor Roseman, David Erritzoe, David Nutt, et al.
Frontiers in Human Neuroscience|July 6, 2016
Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI)Matthew M Nour, Lisa Evans, David Nutt, et al.
BMJ (Clinical Research Ed.)|July 5, 2019
Should the supply of cannabis be legalised now?Molly Meacher, David Nutt, Jonathan Liebling, et al.
Neuroethics|November 9, 2023
When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic ResearchEdward Jacobs, Ashleigh Murphy-Beiner, Ian Rouiller, et al.
The Australian and New Zealand Journal of Psychiatry|June 17, 2016
Reduced heart rate variability in remitted bipolar disorder and recurrent depressionDarryl Bassett, Natasha Bear, David Nutt, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 14, 2016
Inverse agonists - What do they mean for psychiatry?David Nutt, Stephen Stahl, Pierre Blier, et al.
Pageof 18

Showing results (71-80 of 179) with videos related to

Sort By:
Pageof 18
Lancet (London, England)|March 16, 2016
Ketamine--the real perspectivePolly Taylor, David Nutt, Val Curran, et al.
Journal of Psychopharmacology (Oxford, England)|April 30, 2015
European rating of drug harmsJan van Amsterdam, David Nutt, Lawrence Phillips, et al.
Nature Reviews. Neuroscience|April 21, 2011
Neuroscience in recession?Susan G Amara, Sten Grillner, Tom Insel, et al.
Addiction Biology|July 10, 2003
A pilot study on the effects of treatment with acamprosate on craving for alcohol in alcohol-dependent patientsAviv Weinstein, Barbara Feldtkeller, Adrian Feeney, et al.
JAMA Network Open|July 15, 2024
Interrupting the Psychedelic Experience Through Contextual Manipulation to Study Experience EfficacyLeor Roseman, David Erritzoe, David Nutt, et al.
Frontiers in Human Neuroscience|July 6, 2016
Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI)Matthew M Nour, Lisa Evans, David Nutt, et al.
BMJ (Clinical Research Ed.)|July 5, 2019
Should the supply of cannabis be legalised now?Molly Meacher, David Nutt, Jonathan Liebling, et al.
Neuroethics|November 9, 2023
When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic ResearchEdward Jacobs, Ashleigh Murphy-Beiner, Ian Rouiller, et al.
The Australian and New Zealand Journal of Psychiatry|June 17, 2016
Reduced heart rate variability in remitted bipolar disorder and recurrent depressionDarryl Bassett, Natasha Bear, David Nutt, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 14, 2016
Inverse agonists - What do they mean for psychiatry?David Nutt, Stephen Stahl, Pierre Blier, et al.
Pageof 18